相关实验视频

Updated: Jul 20, 2025

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

Published on: August 30, 2014

在儿科过敏性鼻炎中,子语言免疫疗法的疗效和免疫变化

Yinhui Zeng¹, Haiqing Xiao¹, Shengli Gao¹

¹Department of Otolaryngology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangdong Provincial Clinical Research Center for Child Health, Guangzhou, 510623, China.

The World Allergy Organization journal

|July 31, 2023

概括

患有过敏性鼻炎 (AR) 的儿童需要三年次语言下免疫疗法 (SLIT),以获得持续的症状改善和有益的免疫变化,包括增加调节性T细胞.

科学领域:

免疫学免疫学免疫学
过敏学过敏学
儿科儿科儿科

背景情况:

过敏原特异性免疫疗法,包括皮下免疫疗法 (SCIT) 和舌下免疫疗法 (SLIT),对过敏性鼻炎 (AR) 有效.
SLIT的疗效与SCIT相似,系统反应较少,但其潜在的免疫机制需要进一步研究.
了解SLIT对免疫反应的影响对于优化治疗策略至关重要.

研究的目的:

根据不同治疗持续时间,探索在患有过敏性鼻炎 (AR) 的儿童下语言免疫疗法 (SLIT) 的疗效.
调查与不同持续时间的SLIT治疗相关的免疫变化.
确定最佳的治疗持续时间,以实现AR的长期治疗效果.

主要方法:

一项对314名接受ARSLIT治疗的儿童进行回顾性研究,分为1,2,3年治疗组.
使用综合症状和药物评分 (SMS),全鼻症状评分 (TNSS) 和救援药物评分 (RMS) 评估治疗疗效.
分析了血清细胞因子水平 (IL-10,TGF-β,IL-35) 和外周血液单核细胞 (PBMC) 种群 (调节性T细胞,调节性B细胞,毛囊调节性T细胞).

主要成果:

与1年和2年组相比,3年SLIT组在TNSS,RMS和SMS方面表现明显更好.
在SLIT治疗3年后,TNSS,RMS和SMS的显著改善持续了2年治疗结束后.
用SLIT治疗3年导致血清IL-10,TGF-β,IL-35和调节性T细胞,调节性B细胞和毛囊调节性T细胞的百分比显著增加.

结论:

对SLIT治疗3年的治疗持续时间对于在患有过敏性鼻炎的儿童中获得长期临床益处至关重要.
延长SLIT治疗时间促进持续的免疫调节,其特征是增强的调节性免疫细胞群和抗炎性细胞因子.
这些发现强调了治疗坚持和持续时间的重要性,以最大限度地提高SLIT在治疗AR的疗效.

关键词:

过敏过敏过敏过敏细胞因子 (cytokines) 是一种细胞因子.有效性有效性.鼻炎是一种鼻炎.语言下免疫疗法语言下免疫疗法治疗结果的结果.

更多相关视频

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

Basophil Activation Test for Allergy Diagnosis

Basophil Activation Test for Allergy Diagnosis

Published on: May 31, 2021

相关概念视频

Drugs Used in Lower Respiratory Disorders: Overview

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...

Antiasthma Drugs: Leukotriene Modifiers

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:

Allergic Reactions

Allergic Reactions